The temperature dependence of spectra can reveal important insights into the structural and dynamical behavior of the system being probed. In the case of linear spectra, this has been exploited to investigate the thermodynamic driving forces governing the spectral response. Indeed, the temperature derivative of a spectrum can be used to obtain effective energetic and entropic profiles as a function of the measured frequency. The former can further be used to predict the temperature-dependent spectrum via a van't Hoff relation. However, these approaches are not directly applicable to nonlinear, complex-valued spectra, such as vibrational sum-frequency generation (SFG) or two-dimensional infrared (2D-IR) photon echo spectra. Here, we show how the energetic and entropic driving forces governing such nonlinear spectra can be determined and used within a generalized van't Hoff relation to predict their temperature dependence. The central idea is to allow the underlying energetic profiles to themselves be complex-valued. We illustrate this approach for 2D-IR spectra of water and SFG spectra of the air-water interface and demonstrate the accuracy of the generalized van't Hoff relationship and its implications for the origin of temperature-dependent spectral changes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1063/5.0220236 | DOI Listing |
Nat Commun
January 2024
Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF.
View Article and Find Full Text PDFBackground: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.
Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK.
JAMA
November 2023
Research Centre of the Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada.
Importance: The efficacy of vitamin C for hospitalized patients with COVID-19 is uncertain.
Objective: To determine whether vitamin C improves outcomes for patients with COVID-19.
Design, Setting, And Participants: Two prospectively harmonized randomized clinical trials enrolled critically ill patients receiving organ support in intensive care units (90 sites) and patients who were not critically ill (40 sites) between July 23, 2020, and July 15, 2022, on 4 continents.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Behav Res Methods
March 2024
Max Planck Institute for Psycholinguistics, P.O. Box 310, Nijmegen, 6500, AH, The Netherlands.
We introduce the Individual Differences in Language Skills (IDLaS-NL) web platform, which enables users to run studies on individual differences in Dutch language skills via the Internet. IDLaS-NL consists of 35 behavioral tests, previously validated in participants aged between 18 and 30 years. The platform provides an intuitive graphical interface for users to select the tests they wish to include in their research, to divide these tests into different sessions and to determine their order.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!